Comprehensive comparison of health-related quality of life after contemporary therapies for localized prostate cancer.

PURPOSE Health-related quality-of-life (HRQOL) concerns are pivotal in choosing prostate cancer therapy. However, concurrent HRQOL comparison between brachytherapy, external radiation, radical prostatectomy, and controls is hitherto lacking. HRQOL effects of hormonal adjuvants and of cancer control after therapy also lack prior characterization. PATIENTS AND METHODS A cross-sectional survey was administered to patients who underwent brachytherapy, external-beam radiation, or radical prostatectomy during 4 years at an academic medical center and to age-matched controls. HRQOL among controls was compared with therapy groups. Comparison between therapy groups was performed using regression models to control covariates. HRQOL effects of cancer progression were evaluated. RESULTS One thousand fourteen subjects participated. Compared with controls, each therapy group reported bothersome sexual dysfunction; radical prostatectomy was associated with adverse urinary HRQOL; external-beam radiation was associated with adverse bowel HRQOL; and brachytherapy was associated with adverse urinary, bowel, and sexual HRQOL (P < or =.0002 for each). Hormonal adjuvant symptoms were associated with significant impairment (P <.002). More than 1 year after therapy, several HRQOL outcomes were less favorable among subjects after brachytherapy than after external radiation or radical prostatectomy. Progression-free subjects reported better sexual and hormonal HRQOL than subjects with increasing prostate-specific antigen (P <.0001). CONCLUSION Long-term HRQOL after prostate brachytherapy showed no benefit relative to radical prostatectomy or external-beam radiation and may be less favorable in some domains. Hormonal adjuvants can be associated with significant impairment. Progression-free survival is associated with HRQOL benefits. These findings facilitate patient counseling regarding HRQOL expectations and highlight the need for prospective studies sensitive to urinary irritative and hormonal concerns in addition to incontinence, sexual, and bowel HRQOL domains.

[1]  J. Neter,et al.  Applied linear statistical models : regression, analysis of variance, and experimental designs , 1974 .

[2]  E. Crawford,et al.  Radical retropubic prostatectomy. , 1983, The Journal of urology.

[3]  C. Sherbourne,et al.  The MOS 36-Item Short-Form Health Survey (SF-36) , 1992 .

[4]  D. Tulsky,et al.  The Functional Assessment of Cancer Therapy scale: development and validation of the general measure. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  John E. Ware,et al.  SF-36 physical and mental health summary scales : a user's manual , 1994 .

[6]  R H Brook,et al.  Quality-of-life outcomes in men treated for localized prostate cancer. , 1995, JAMA.

[7]  A. Brickman,et al.  Quality of life: radical prostatectomy versus radiation therapy for prostate cancer. , 1995, The Journal of urology.

[8]  T. Stamey,et al.  Incontinence and vesical neck strictures following radical retropubic prostatectomy. , 1995, Urology.

[9]  M. Barry,et al.  Outcomes of external-beam radiation therapy for prostate cancer: a study of Medicare beneficiaries in three surveillance, epidemiology, and end results areas. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  P L Roberson,et al.  Optimal placement of radioisotopes for permanent prostate implants. , 1996, Radiology.

[11]  C. McPherson,et al.  Quality of life and treatment outcomes , 1997, Cancer.

[12]  K. Pienta,et al.  Measuring quality of life in men with prostate cancer using the functional assessment of cancer therapy-prostate instrument. , 1997, Urology.

[13]  M. Piérart,et al.  Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. , 1997, The New England journal of medicine.

[14]  J. Richie,et al.  Patient-reported impotence and incontinence after nerve-sparing radical prostatectomy. , 1997, Journal of the National Cancer Institute.

[15]  H. Sandler,et al.  Results of 3D conformal radiotherapy in the treatment of localized prostate cancer. , 1997, International journal of radiation oncology, biology, physics.

[16]  J. Blasko,et al.  Interstitial iodine‐125 radiation without adjuvant therapy in the treatment of clinically localized prostate carcinoma , 1997, Cancer.

[17]  A. Renshaw,et al.  Biochemical Outcome after radical prostatectomy, external beam Radiation Therapy, or interstitial Radiation therapy for clinically localized prostate cancer , 1998 .

[18]  F. Joly,et al.  Health-related quality of life and sequelae in patients treated with brachytherapy and external beam irradiation for localized prostate cancer. , 1998, Annals of oncology : official journal of the European Society for Medical Oncology.

[19]  R. Stock,et al.  Identification of patients at increased risk for prolonged urinary retention following radioactive seed implantation of the prostate. , 1998, The Journal of urology.

[20]  J. Richie,et al.  Patient-reported symptoms after primary therapy for early prostate cancer: results of a prospective cohort study. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  D. Lubeck,et al.  Differences in urologist and patient assessments of health related quality of life in men with prostate cancer: results of the CaPSURE database. , 1998, The Journal of urology.

[22]  R H Brook,et al.  The UCLA Prostate Cancer Index: development, reliability, and validity of a health-related quality of life measure. , 1998, Medical care.

[23]  M. Barry.  Quality of life and prostate cancer treatment. , 1999, The Journal of urology.

[24]  A W Partin,et al.  Natural history of progression after PSA elevation following radical prostatectomy. , 1999, JAMA.

[25]  J. Manola,et al.  Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. , 1999, The New England journal of medicine.

[26]  A. D'Amico,et al.  Prostate brachytherapy , 1999, Cancer.

[27]  J. Stanford,et al.  Prostate cancer practice patterns and quality of life: the Prostate Cancer Outcomes Study. , 1999, Journal of the National Cancer Institute.

[28]  D. Kuban,et al.  Radiation therapy for clinically localized prostate cancer: a multi-institutional pooled analysis. , 1999, JAMA.

[29]  W. Lee,et al.  Early quality of life assessment in men treated with permanent source interstitial brachytherapy for clinically localized prostate cancer. , 1999, The Journal of urology.

[30]  M. Barry.  EDITORIAL: QUALITY OF LIFE AND PROSTATE CANCER TREATMENT , 1999 .

[31]  R A Stephenson,et al.  Health outcomes after prostatectomy or radiotherapy for prostate cancer: results from the Prostate Cancer Outcomes Study. , 2000, Journal of the National Cancer Institute.

[32]  H M Sandler,et al.  Development and validation of the expanded prostate cancer index composite (EPIC) for comprehensive assessment of health-related quality of life in men with prostate cancer. , 2000, Urology.

[33]  M. Litwin,et al.  Quality of life outcomes after brachytherapy for early stage prostate cancer. , 2000, The Journal of urology.

[34]  R A Stephenson,et al.  Urinary and sexual function after radical prostatectomy for clinically localized prostate cancer: the Prostate Cancer Outcomes Study. , 2000, JAMA.